problendoПроблемы ЭндокринологииProblems of Endocrinology0375-96602308-1430Endocrinology Research Centre10.14341/probl20105653-7problendo-4746Research ArticleСтатьиArticlesЭпидемиология первичного гиперпаратиреозаEpidemiology of primary hyperparathyroidismDedovI I-Vasil'evaT O-RozhinskaiaL Ia-MokryshevaN G-201015102010565ТОМ 56, №5 (2010)37Copyright © Dedov I.I., Vasil'eva T.O., Rozhinskaia L.I., Mokrysheva N.G., 20102010Dedov I.I., Vasil'eva T.O., Rozhinskaia L.I., Mokrysheva N.G.Dedov I.I., Vasil'eva T.O., Rozhinskaia L.I., Mokrysheva N.G.Данная работа распространяется под лицензией Creative Commons Attribution 4.0.This work is licensed under a Creative Commons Attribution 4.0 License.https://www.probl-endojournals.ru/jour/article/view/4746

До середины 70-х годов XX века первичный гиперпаратиреоз (ПГПТ) считали крайне редким заболеванием. После введения в клиническую практику исследования уровня кальция крови, представления о его распространенности и многообразии клинических признаков претерпели значительные изменения. Представленный обзор литературы демонстрирует результаты немногочисленных исследований эпидемиологии ПГПТ, проведенных в различных странах.

Up to the mid-1970s, primary hyperparathyroidism (PHPT) was considered to be a rare pathology. The introduction of methods for the measurement of blood calcium levels into the clinical practice substantially extended knowledge about diverse forms of PHPT and its prevalence. The present review presents results of those sparse epidemiological investigations of PHPT that were carried out in different countries.

первичный гиперпаратиреозэпидемиологияprimary hyperparathyroidismepidemiologyReferencesHedback G., Oden A. Death risk factor analysis in primary hyperparathyroidism. Eur J Clin Inv 1998;28:1011-1018.Hedback G., Oden A. Death risk factor analysis in primary hyperparathyroidism. Eur J Clin Inv 1998;28:1011-1018.The American Association of clinical endocrinologists and The American Association of endocrine surgeons. Position statement on the diagnosis and management of primary hyperparathyroidism. Endocrine Pract 2005;11:1.The American Association of clinical endocrinologists and The American Association of endocrine surgeons. Position statement on the diagnosis and management of primary hyperparathyroidism. Endocrine Pract 2005;11:1.DeLellis R.A., Mazzaglia P., Mangray S. Primary hyperparathyroidism: a current perspective. Arch Pathol Lab Med 2008;132:8:1251-1262.DeLellis R.A., Mazzaglia P., Mangray S. Primary hyperparathyroidism: a current perspective. Arch Pathol Lab Med 2008;132:8:1251-1262.Adami S., Marcocci C., Gatti D. Epidemiology of primary hyperparathyroidism in Europe. J Bone Miner Res 2002;17:Suppl 2:N18-N23.Adami S., Marcocci C., Gatti D. Epidemiology of primary hyperparathyroidism in Europe. J Bone Miner Res 2002;17:Suppl 2:N18-N23.Ning Yu, Peter T. Donnan, Michael J. Murphy and Graham P. Leese. Epidemiology of primary hyperparathyroidism in Tayside, Scotland, UK. J Clin Endocrinol 2009;71:485-493.Ning Yu, Peter T. Donnan, Michael J. Murphy and Graham P. Leese. Epidemiology of primary hyperparathyroidism in Tayside, Scotland, UK. J Clin Endocrinol 2009;71:485-493.Heath H., Hodgson S.F., Kennedy M.A. Primary hyperparathyroidism. Incidence, morbidity, and potential economic impact in a community. New Engl J Med 1980;302:189-193.Heath H., Hodgson S.F., Kennedy M.A. Primary hyperparathyroidism. Incidence, morbidity, and potential economic impact in a community. New Engl J Med 1980;302:189-193.How to treat. Hyperparathyroidism. Australian doctor 2002;4-8.How to treat. Hyperparathyroidism. Australian doctor 2002;4-8.Wermers R.A., Atkinson E.J, Achenbach S.J. et al. Incidence of primary hyperparathyroidism in Rochester, Minnesota, 1993-2001: an update on the changing epidemiology of the disease. J Bone Miner Res 2006;21:1:171-177.Wermers R.A., Atkinson E.J, Achenbach S.J. et al. Incidence of primary hyperparathyroidism in Rochester, Minnesota, 1993-2001: an update on the changing epidemiology of the disease. J Bone Miner Res 2006;21:1:171-177.Melton L.J. 3rd. Mayo Clinic, Rochester, Minnesota, USA. The rise and fall of primary hyperparathyroidism: a population-based study in Rochester, Minnesota, 1965-1992. Ann Int Med 1997;126:6:433-440.Melton L.J. 3rd. Mayo Clinic, Rochester, Minnesota, USA. The rise and fall of primary hyperparathyroidism: a population-based study in Rochester, Minnesota, 1965-1992. Ann Int Med 1997;126:6:433-440.Morris A.D., Boyle D.I., MacAlpine R. et al. The diabetes audit and research in Tayside Scotland (DARTS) study: electronic record linkage to create a diabetes register. DARTS/MEMO Collaboration. Br Med J 1997;315:524-528.Morris A.D., Boyle D.I., MacAlpine R. et al. The diabetes audit and research in Tayside Scotland (DARTS) study: electronic record linkage to create a diabetes register. DARTS/MEMO Collaboration. Br Med J 1997;315:524-528.Flynn R.W., Macdonald T.M., Jung R.T. et al. Mortality and vascular outcomes in patients treated for thyroid dysfunction. J Clin Endocrinol Metabol 2006;91:2159-2164.Flynn R.W., Macdonald T.M., Jung R.T. et al. Mortality and vascular outcomes in patients treated for thyroid dysfunction. J Clin Endocrinol Metabol 2006;91:2159-2164.The Mattson Jack Group. Epidemiology of Primary Hyperparathyroidism in Europe - report commissioned by Amgen. 2003.The Mattson Jack Group. Epidemiology of Primary Hyperparathyroidism in Europe - report commissioned by Amgen. 2003.Blichert-Toft M., Mollerup C.L., Feldt-Rasmussen U.F. et al. [Primary hyperparathyroidism. An underdiagnosed disease in Denmark. Ugeskr Laeger 1993;155:765-769.Blichert-Toft M., Mollerup C.L., Feldt-Rasmussen U.F. et al. [Primary hyperparathyroidism. An underdiagnosed disease in Denmark. Ugeskr Laeger 1993;155:765-769.Nilsson I.L., Yin L., Lundgren E. et al. Clinical presentation of primary hyperparathyroidism in Europe -nationwide cohort analysis on mortality from nonmalignant causes. J Bone Miner Res 2002;17:Suppl 2:N68.Nilsson I.L., Yin L., Lundgren E. et al. Clinical presentation of primary hyperparathyroidism in Europe -nationwide cohort analysis on mortality from nonmalignant causes. J Bone Miner Res 2002;17:Suppl 2:N68.Jorde R., Bonaa K.H., Sundsfjord J. Primary hyperparathyroidism detected in a health screening. The Tromso study. J Clin Epidemiol 2000;53:1164-1169.Jorde R., Bonaa K.H., Sundsfjord J. Primary hyperparathyroidism detected in a health screening. The Tromso study. J Clin Epidemiol 2000;53:1164-1169.Palmér M., Jakobsson S., Akerström G., Ljunghall S. Prevalence of hypercalcaemia in a health survey: a 14-year follow-up study of serum calcium values. Eur J Clin Inv 1988;18:1:39-46.Palmér M., Jakobsson S., Akerström G., Ljunghall S. Prevalence of hypercalcaemia in a health survey: a 14-year follow-up study of serum calcium values. Eur J Clin Inv 1988;18:1:39-46.Richerta L., Trombettia A., Herrmanna F.R. et al. Age and gender distribution of primary hyperparathyroidism and incidence of surgical treatment in a European country with a particularly high life expectancy. Swissmedwkly 2009;139:27-28.Richerta L., Trombettia A., Herrmanna F.R. et al. Age and gender distribution of primary hyperparathyroidism and incidence of surgical treatment in a European country with a particularly high life expectancy. Swissmedwkly 2009;139:27-28.Rubin M.R., Bilezikian J.P., McMahon, D.J. et al. The natural history of primary hyperparathyroidism with or without parathyroid surgery after 15 years. J Clin Endocrinol Metabol 2008;93:3462-3470.Rubin M.R., Bilezikian J.P., McMahon, D.J. et al. The natural history of primary hyperparathyroidism with or without parathyroid surgery after 15 years. J Clin Endocrinol Metabol 2008;93:3462-3470.Polyzois Makras, Socrates E. Papapoulos Medical treatment of hypercalcaemia. Hormones 2009;8:2:83-95.Polyzois Makras, Socrates E. Papapoulos Medical treatment of hypercalcaemia. Hormones 2009;8:2:83-95.Bilezikian, JP, Silverberg, SJ, Shane, E, et al. Characterization and evaluation of asymptomatic primary hyperparathyroidism. J Bone Miner Res 1991;6:Suppl 2:S85.Bilezikian, JP, Silverberg, SJ, Shane, E, et al. Characterization and evaluation of asymptomatic primary hyperparathyroidism. J Bone Miner Res 1991;6:Suppl 2:S85.Khan Bilezikian. Primary hyperparathyroidism: pathophysiology and impact on bone. CMAJ 2000;163:2.Khan Bilezikian. Primary hyperparathyroidism: pathophysiology and impact on bone. CMAJ 2000;163:2.Trump D., Farren B., Wooding C. et al. Clinical studies of multiple endocrine neoplasia type 1 (MENI). Q J Med 1996;89:653-669.Trump D., Farren B., Wooding C. et al. Clinical studies of multiple endocrine neoplasia type 1 (MENI). Q J Med 1996;89:653-669.Beers M.H., Berkow R. (Eds.). The Merck manual of diagnosis and therapy. 17th ed. West Point, PA. Merck & Co Inc 1999.Beers M.H., Berkow R. (Eds.). The Merck manual of diagnosis and therapy. 17th ed. West Point, PA. Merck & Co Inc 1999.Brandi M.L., Gagel R.F., Angeli A. et al. Guidelines for diagnosis and therapy of MEN type 1 and type 2. J Clin Endocrinol Metab 2001;86.Brandi M.L., Gagel R.F., Angeli A. et al. Guidelines for diagnosis and therapy of MEN type 1 and type 2. J Clin Endocrinol Metab 2001;86.Uchino S., Noguchi S., Sato M. et al. Screening of the MEN1 gene and discovery of germ-line and somatic mutations in apparently sporadic parathyroid tumors. Cancer Res 2000;60:5553-5557.Uchino S., Noguchi S., Sato M. et al. Screening of the MEN1 gene and discovery of germ-line and somatic mutations in apparently sporadic parathyroid tumors. Cancer Res 2000;60:5553-5557.Marx S.J. Multiple endocrine neoplasia type 1. In: The metabolic and molecular bases of inherited disease. Eds. C.R. Scriver, A.L. Beaudet, W.S. Sly, D. Valle. 8-th. New York: McGraw-Hill 2001;943-966.Marx S.J. Multiple endocrine neoplasia type 1. In: The metabolic and molecular bases of inherited disease. Eds. C.R. Scriver, A.L. Beaudet, W.S. Sly, D. Valle. 8-th. New York: McGraw-Hill 2001;943-966.

The authors declare that there are no conflicts of interest present.